Palliative radiation plus pembrolizumab for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join the study (and you’re at least 18 years old).
- You have confirmed breast cancer that is stage IV and cannot be removed by surgery or has spread to other parts of the body.
- You are able to get palliative SBRT (a targeted radiation approach) for comfort, outside of the study plan.
- You have measurable tumors on scans (with specific size rules for lesions or lymph nodes).
- You have had two prior treatments for metastatic disease, including a taxane medicine.
- Your blood tests, kidney/liver tests, and overall functioning are within the study’s safety limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
This trial tests whether giving radiation to a few growing spots (1-3) can let you stay on your current drug longer, instead of switching to a new one right away. It's for people with metastatic breast cancer whose disease has been stable for months but now shows limited progression.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.